Executive Search Success Story: Building Commercialization Leadership for Combination-Product Launches

How JRG Partners executed a highly confidential, multi-role North American retained search strategy that equipped a global specialty pharmaceutical company with the critical commercial operations, product development, global quality, and engineering leadership required to commercialize combination products, navigate regulatory scrutiny, and de-risk the commercial launch of therapies using advanced drug delivery technologies.

The Challenge

A global specialty pharmaceutical company was preparing to launch multiple therapies utilizing sophisticated drug delivery technologies—including wearable injectors, autoinjectors, and long-acting platforms. To ensure smooth international commercialization, satisfy rigid health authority mandates, and secure long-term market growth, the enterprise required an entirely new layer of cross-functional executive management. Corporate leadership identified several intense operational and market pressures:

• Highly limited internal executive expertise in the specific nuances of drug-device combination-product commercialization
• Increasingly complex global regulatory scrutiny specifically targeting integrated drug-device products
• Severe competitive pressure from established, well-capitalized pharmaceutical organizations
• Acute manufacturing-readiness and technical scale-up concerns ahead of strict commercial delivery deadlines
• Pronounced product-launch execution, distribution, and clinical adoption risks
• Severe talent shortages across both advanced device engineering and combination-product regulatory functions

The company’s board and CEO determined that mitigating these high-stakes launch risks required a synchronized corporate management structure spanning a VP Commercial Operations, VP Combination Product Development, VP Global Quality, Director of Device Engineering, Director of Program Management, and associated regulatory and commercialization leaders. Successfully executing this mandate required a search partner combining exact vertical literacy in combination-product validation with an immediate connection to a nationwide network of passive life-sciences talent. For organizations analyzing how technical engineering teams scale early-stage development lines prior to executing commercial launch pathways, a parallel analysis can be reviewed in Drug_Delivery_Systems_A_Whitelabeled.docx.

Why They Chose JRG Partners

Deep Combination-Product Commercialization Specialization

Unlike generalist recruitment firms that lack functional immersion in cross-disciplinary therapeutic platforms, JRG Partners maintains dedicated executive search practices built explicitly around combination-product development, commercial operations, global quality governance, and regulatory leadership. Our consultants carry an intimate operational understanding of the tight verification, scaling, and market-entry windows mandatory in the specialty pharmaceutical space.

Real Access to Passive Talent

The most effective commercialization leaders and quality directors within the combination-product sector are typically fully embedded in active commercial lifecycles and rarely monitor public job listings. JRG Partners bypassed conventional recruitment channels entirely, leveraging long-standing sector relationships, pharmaceutical networks, and proprietary market intelligence to directly engage high-performing passive leaders invisible to standard sourcing methods.

Confidential Search Execution

Because this management build-out took place concurrently with high-stakes product launches, sensitive commercialization metrics, and critical global growth plans, absolute discretion was a mandatory requirement. JRG Partners ran a highly secure, confidential vetting framework that successfully protected the client’s competitive advantages, preserved organizational continuity, and maintained total stakeholder confidence.

True North American Life-Sciences Reach

Sourcing specialized commercial and technical talent capable of guiding a global launch required an outreach strategy unconstrained by geography. JRG Partners deployed a coordinated strategy across primary life-sciences and biotech hubs throughout the United States and Canada, delivering a premium shortlist of proven, cross-border executives to the client’s board.

Our Executive Search Strategy

Phase 1 — Strategic Alignment & Competency Assessment

Our consultants partnered directly with the CEO, Board, and executive team to systematically map existing organizational gaps, identify hidden launch execution risks, clarify commercialization objectives, and define the exact leadership competencies required for long-term growth. Rather than matching against legacy job descriptions, we built forward-looking executive profiles dynamically tied to the company’s multi-year international launch strategy.

Phase 2 — Multi-Sector Market Mapping

JRG Partners executed an exhaustive market-mapping initiative that targeted high-performing, process-driven engineering and commercial environments across North America. Our comprehensive market map targeted key talent pools across pharmaceutical manufacturers, specialty pharmaceutical companies, biotechnology organizations, drug-device combination product companies, medical technology businesses, contract manufacturing organizations (CMOs), and product-commercialization specialists.

Phase 3 — Targeted Executive Engagement

Using a research-driven, discreet outreach framework, our consultants directly contacted and evaluated high-achieving executives with verified records of success in combination-product launches, commercial scaling, and global quality assurance. Only candidates demonstrating clear, measurable operational, quality, and commercialization impact advanced to the final evaluation round.

Phase 4 — Rigorous Assessment & Final Selection

Each finalist candidate underwent an extensive evaluation process looking far beyond basic professional credentials. Our consultants conversion-tested strategic and functional capabilities, combination-product regulatory agility, team-building and leadership philosophies, cross-functional communication skills, cultural alignment with rapid commercial scaling, and long-term retention potential.

Key Outcomes

• 500+ targeted combination-product commercialization, specialty pharmaceutical, and medical device engineering executive profiles systematically mapped across key North American life-sciences corridors.
• Successfully placed and integrated a complete corporate leadership framework—spanning the VP level, device engineering directors, and commercialization leaders—within a 10-month timeline.
• Unified separate cross-functional engineering and commercial groups under a single, cohesive launch strategy by installing regulatory-grade transformation executives.
• Accelerated advanced wearable and autoinjector platform integration by placing forward-thinking combination product development and device engineering directors.
• Mitigated manufacturing-readiness risks and optimized supply chain alignment by placing specialized, data-driven program management leaders.
• Protected crucial commercial pipelines, sensitive regulatory filing roadmaps, and unreleased device specifications during a high-stakes transition phase through strict search confidentiality.
• Provided the Board of Directors and CEO with a high-performance management framework explicitly equipped to eliminate long-term succession risks and drive profitable combination-product innovation.